T he objectives of this study were to describe the global geographic variation of microvascular and macrovascular complications in childhood onset type 1 diabetes (T1D) and to relate any such variation to diabetes care activities such as self blood glucose monitoring and intensive insulin therapy.
Introduction
Type 1 diabetes (T1D) carries a substantial risk of morbidity and early mortality due to its numerous complications. 1 While T1D has a much lower worldwide incidence than type 2 diabetes, the loss of quality life-years for those with T1D is especially large due to the earlier onset of disease and the greater degree of glycaemic exposure. Extensive data are available on the occurrence of T1D in globally diverse populations: for example, the WHO Diabetes Mondiale (DiaMond) Study examined the incidence of T1D in more than 100 geographically varied centres and demonstrated a 36-fold variation from high rates in northern Europe to low rates in Asia and South America. 2 However, relatively little is known about geographic variation in complication rates and many of the data that are available are not derived from population-based samples.
One notable exception is the World Health Organization (WHO) Multinational Study of Vascular Disease in Diabetes (MSVDD), which examined the prevalence and incidence of macrovascular and microvascular complications in individuals with both type 1 and type 2 diabetes. 3 Another major study, EURODIAB, examined complication prevalence in a crosssectional report of T1D subjects from 16 European countries, with ages ranging from 15 to 60 years and a mean duration of diabetes of 14.7 years. 4 However, the fact that these studies were clinic-based constitutes a major drawback.
In order to investigate further the geographic variation in T1D complications and their underlying determinants, using population-based (or otherwise representative) samples, a substudy of the WHO DiaMond study, called DiaComp, was initiated in 1995. Analyses are specifically focused on the roles of intensive insulin therapy (IIT) and self-monitoring of blood glucose (SMBG) in explaining the geographic variation of complications. These facets of care are advocated by many national authorities such as the American Diabetes Association (ADA) guidelines and are thought to be critical to achieving good glycaemic control and thus minimising complication rates, as demonstrated by the Diabetes Control and Complications Trial (DCCT). 5 SMBG was shown to be particularly important for glycaemic control in the Northern California Kaiser Permanente Diabetes registry, 6 although a meta-analysis of SMBG in type 2 diabetes suggests that the evidence remains inconclusive. 7 The DiaComp study overall comprised 25 centres in 18 countries from Asia, Africa, Australia, Europe, and North and South America. Information on complications, healthcare practices and other risk factors was collected at two levels.
This report concerns self-reported complications and healthcare practices (Level 1), using representative study populations. A subsequent report will detail the examination (Level 2) findings for directly measured complications and risk factors. The objectives of this report are first, to describe the geographic variation of reported complications, and second, to explain any observed variation in terms of reported healthcare practices, with the expectation that individuals and centres that practice self blood glucose monitoring and/or intensive insulin therapy will demonstrate lower complication rates.
Research design and methods
DiaComp is a substudy of the WHO Diabetes Mondiale (DiaMond) study of type 1 diabetes incidence, the methods of which have been described elsewhere. 2 Briefly, the DiaMond study was a collaboration between the WHO, the University of Pittsburgh and the National Public Health Institute, Helsinki, Finland and included 100 centres in 50 countries. Its goal was to use standardised methods to identify and characterise T1D. The 1985 WHO classification of diabetes and diagnostic criteria 8 were used to determine T1D cases. Participants had to have been diagnosed with T1D at less than 15 years of age, to be on insulin therapy at the time of diagnosis and to be a resident of a defined community, which was defined geographically to correspond with administrative and census boundaries.
The current report concerns an interviewer-administered survey to ascertain physician-diagnosed complications, healthcare practices and behaviour. Thirteen centres from the DiaMond study were included and have previously been described. 2 In addition, a further 11 centres were recruited specially, representing either large, major or exclusive sources of care or formal (non-DiaMond) registries. Three of the non-DiaMond centres (Sweden, Tasmania and Japan [nationwide]) were registries; eight of the centres (Rio, Pittsburgh, Osaka, Libya, Israel and the three Argentinian centres) represented large sources of diabetes care. Osaka, Libya and Rosario, Argentina recruited patients from either most or all of the city hospitals where patients with type 1 diabetes would be seen. Pittsburgh and Israel recruited patients through children's hospitals and those living within a 100and 50-mile radius, respectively, of the hospital. The Pittsburgh Children's Hospital registry has previously been shown to be epidemiologically representative of the local Allegheny County. 9 The Buenos Aires and Rio centres recruit-ed participants seen from both public hospitals and private practice, though these institutions were not all-inclusive.
The inclusion criteria consisted of age at diagnosis < 15 years and a diabetes duration between 5.0 and 24.99 years. Two of the 24 centres that initially took part achieved less than a 67% response rate based on their sampling frame and were thus excluded, leaving 22 centres with a sampling frame of 3,340 participants. Of these, 129 participants were determined to be ineligible (50 had died and 79 had moved), leaving 3,211 eligible, of whom 83% responded (2,657) and are described in table 1.
Survey
Each individual personally completed a 10-20 minute interview (parents could be present in the case of children). Questions included history of physician-diagnosed complications, healthcare behaviours, history of disability, smoking status, level of education completed, occupational history, height, weight, medication use, the Michigan Neuropathy Screening Instrument (MNSI) questionnaire, 10 and the Rose Questionnaire for angina. 11 Self-reported physician-diagnosed complications included retinopathy and laser treatment, neuropathy, renal disease, hyperlipidaemia (high cholesterol and/or triglycerides), hypertension, and macrovascular complications including myocardial infarction, stroke, peripheral vascular disease, amputation and angina. All of these were determined by response to the question, "Has a physician ever told you that you have…?"
Collection of data was standardised by using the same survey translated into the local language. Before the centre was allowed to collect data, three steps had to be completed. First, the forms were independently translated back into English from each local language and any differences resolved. Second, a detailed discussion of the proposed local methodology (to identify, recruit and interview participants) had to be completed between one of the chairs of the steering committee and the local principal investigators for approval of the methodology. Following approval, all centres had to register with the coordinating centre by formally documenting all eligible cases and detailing the strategy to be employed for recruitment. Third, a detailed Manual of Operations, including instructions for each question in the survey, was distributed to all centres, and presented to leading investigators from each centre at one (or more) of eight training workshops.
Data collection in Pittsburgh and study-wide analyses were approved by the University of Pittsburgh Institutional Review Board, while local centres were required to seek their own human volunteer committee approval. Appropriate sampling within each centre was further validated with a follow-up survey that required further documentation of the sampling frame, which was compared to the completed surveys and face sheets (which gave detailed information on non-participation for all individuals who were eligible but did not participate) received at the coordinating centre.
Statistical analyses
Both centre-based and individual data were analysed. Centre-based analyses included correlation coefficients between centre complication prevalence and the mean number of insulin injections per day. Odds ratios (OR) were computed using individual data to test the association between the presence of complications and the putative correlate, intensive insulin therapy (IIT). Both the correlations for the grouped data and the bivariate OR were used to show the overall effect of IIT before subsequently controlling for centre. Logistic regression was used for the individual data to model the effect of centre on the prevalence of complications. Each model contained indicator variables representing the centres with a prevalence of the specific complication greater than zero. All analyses were verified with exact logistical regression; no differences were demonstrated between the asymptotic and exact models. Therefore, the asymptotic models are presented.
Subsequently, three models were compared. The first model included only the centre effects. The second included the centre effects plus the demographic variables, duration of diabetes and gender of the patient. The third includ-ORIGINAL ARTICLE DIABETES AND VASCULAR DISEASE RESEARCH 
Results
The distributions of demographics (age, duration and gender) showed little variation across centre, as intended (table  1) , whereas the distributions of access to care and diabetes care practices showed substantial variation across centres (table 2) .
The prevalence of complications also shows substantial variation for nearly all complications in both short-and longduration groups (table 3) . History of retinopathy and laser treatment in the short-duration group were quite uncommon in the South American centres (2.7-9.5%), but more common in the eastern European centres. In the long-duration group, prevalence was low in Osaka (25.7%) and high in Libya (65%) and Australia (62.7%). History of neuropathy Key: *MDVISIT1 is the proportion who have been to see a physician at least once in the previous year; **MDVISIT2 is the mean number of physician visits in the previous year; + SMBG is the proportion of those who check blood glucose at least once per week; ++ IIT is the proportion of those who practise intensive insulin therapy, i.e. > 2 injections/day. and hyperlipidaemia also varied widely across all centres for both short-and long-duration groups, while a history of kidney disease, hypertension and macrovascular disease varied substantially in the long-duration group only. The high rates of macrovascular disease in Chicago (US), Puerto Rico, Rio de Janeiro (Brazil) and Cuba were largely due to angina and peripheral vascular disease.
Correlations between the centre-specific prevalence of complications and mean number of insulin injections per day were all inverse, but results for the MNSI (r=-0.37) and macrovascular disease (r=-0.40) approached significance (p=0.09 and p=0.07, respectively). The odds ratios, based on individual data, for each complication in association with the presence of intensive insulin therapy (> 2 injections/day), however, were generally in the opposite direction, being positive. They were significant for reported CI=0.6-0.9) showed significant inverse associations. Summaries of the multiple logistic regression models are presented in table 4. These models are based on complication status at the individual level, with a subject's centre being entered as an explanatory variable. The effect of adjustment for demographic variables is shown in Model 2 and the effect of further adjustment for healthcare practice in Model 3. Only centres whose effect in Model 1 was significant are shown. A major reduction in centre effects occurred after controlling for the demographic variables, duration of diabetes and gender. There was relatively little effect of controlling for healthcare variables. For example, the high prevalences of retinopathy in Lithuania, Romania, Libya and Australia were still apparent despite significant prediction by smoking, gender and, in particular, hypertension (OR=5.7, 95% CI 4.1-7.8). The much lower prevalences of laser treatment showed a similar pattern, with the high rate in Lithuania remaining unexplained (OR=16.5, 95% CI 2.0-136.2). For neuropathy (reported), the high risk for Lithuania and Romania remained despite controlling for smoking, number of physician visits and hypertension, which were predictive (Model 3). For renal disease, the higher rates in Cuba, Japan (nationwide), Israel, Rosario and Australia were largely explained by demographics (Model 2), although smoking, number of physician visits and hypertension predicted and accounted for some of the rates in Cuba, Japan (nationwide), Rio de Janeiro and Australia (Model 3). Effects of centre were not substantially reduced for other complications after introducing the demographic and healthcare practice variables (data not shown).
Discussion
This study shows that all reported complications show considerable variability in worldwide prevalence across centre, e.g. retinopathy (8-fold), laser treatment (14-fold), neuropathy (20-fold), hypertension (4-fold) and macrovascular complications (10-fold). Despite comparable demographics, this variation was particularly apparent in the shorter-duration group, perhaps suggesting that areas with a specific susceptibility can show an earlier onset of complications before the predominance of duration and glycaemic exposure comes into play. Retinopathy and laser therapy were strikingly common in central Europe in the short-duration group and in Australia for the long-duration group. Neuropathy, by either measure, as well as macrovascular disease and its risk factors, appear high in the Caribbean for both duration groups, and in the US (Chicago) for the short-duration group. Moreover, healthcare practices and behaviours, including frequency of physician visits, smoking, SMBG and IIT, varied markedly across region in both duration groups but explained little of the variation either within or across centres. A history of hypertension was a powerful correlate of complication prevalence but explained little of the geographic variation.
For this (Level 1) component of DiaComp, complication prevalence was assessed by recall of physician diagnoses alone, a measure that requires five key steps. First, a physician must diagnose the condition. Second, the physician must inform the patient of the diagnosis. Third, the individual must understand and retain the diagnosis information. Fourth, the individual must be able to recall the diagnosis over time. Finally, the individual must be willing to communicate this diagnosis with others. Clearly, self-reported diagnoses of complications are potentially limited by failure or bias at any of the above stages, which may vary across centres. For example, centres may vary in active screening for urinary albumin, or in the threshold used to inform patients (e.g. microalbuminuria vs. frank proteinuria). Self-reported inaccuracy has been shown to be present but fairly moderate in many chronic disease conditions, including ischaemic heart disease (16%), cataracts (17%), hip fracture (19%), lung cancer (22%), prostate cancer (25%), colon cancer (29%) and stroke (33%). 12 A high degree of sensitivity (91%) for selfreporting of hypertension has been reported. 13 Nevertheless, caution must apply when interpreting results when selfreport is the only measure of disease presence. These limitations in the assessment of complications and risk factors are diminished in our Level 2 study where a greater variety of measures is assessed directly, although this subgroup is substantially smaller. Indeed, these data were used to assess the agreement between self-reported and directly measured complication status for neuropathy, hypertension and renal disease. 14 Agreement was strong and significant for neuropathy (r=0.5, p<0.05) and hypertension (r=0.61, p<0.01). 14 Age and duration of diabetes were generally associated with most complications, except neuropathy. Women had a significantly higher prevalence of retinopathy, laser treatment and kidney disease (table 4). Of the behavioural risk factors and healthcare practices, ever having smoked was an important predictor of laser treatment, neuropathy and renal disease, as was the frequency of physician visits. Though renal disease showed some variation among centres, which could be due to differences in screening practices between centres, after controlling for duration and gender the rates of renal disease did not differ significantly between centres (table 4) .
Hypertension was strongly and significantly associated with all complications in a positive direction. This is consistent with many other studies which show hypertension to be related to retinopathy, 15,16 nephropathy 17 and neuropathy 18 and should give further impetus to blood pressure control. The effects of SMBG and IIT appeared minimal for either the centre-specific data or the individual data (table 4) , where there was virtually no reduction in centre effect for retinopathy, kidney disease and neuropathy when the healthcare practice variables were added. We conclude, therefore, that although duration for most complications, and female gender for some complications, made a significant contribution to geographic variation, the healthcare and practice variables as measured contributed little toward explaining the geographic variation observed in DiaComp, with the possible exceptions of Cuba (renal disease) and Japan (laser treatment and renal disease).
It is surprising that IIT in particular was not linked more closely with complication prevalence. However, as these are cross-sectional data our findings may reflect, to a varying degree, reverse causality. In other words, those with complications go on to IIT as a result of developing a complication, thus obscuring any benefit. This is the most likely explanation for the positive odds ratios for retinopathy and neuropathy with IIT, as described. The same argument may also apply to SMBG. Another concern is that IIT or SMBG alone, which were seen quite often, is unlikely to be very helpful. Although a direct causal association between IIT or SMBG and complications could not be demonstrated, results from the DCCT provide clear evidence for the role of an intensive regimen designed to improve glycaemic control and reduce the incidence of complications. In the DCCT, IIT was defined as three or more insulin injections per day (the same definition used in these analyses), with dosage adjustments made according to the results of SMBG. As the goal for treatment is to achieve blood glucose levels in the normal range, daily SMBG plays a critical role in reaching this goal. 19 Finally, SMBG and IIT may reflect different aspects of care in different centres. For example, centres in high-income areas may use SMBG and IIT in everyone whereas centres in lowincome areas may limit SMBG and IIT to individuals who develop complications.
This question of regional variation will be more directly addressed cross-sectionally in Level 2, where clinical measures of glycaemic control, blood pressure and complications are available. The cross-sectional nature of this study is a major limitation and precludes definitive answers. The identification of causal relationships will require a longitudinal assessment of complications development in geographically diverse type 1 diabetes populations, focusing on the effect of healthcare access and practice as well as personal diabetes management. There will of necessity be differences across centres in the thresholds established to diagnose and manage both hypertension and hyperlipidaemia. Therefore, we cannot rule out the possibility that variation in the prevalence of these may be due to variation in standard diabetes care.
The WHO Multinational Study of Vascular Disease in Diabetes (MSVDD), which examined the incidence of complications in both type 1 and type 2 diabetes, has also shown variation in incidence rates across geographic region. 3 However, MSVDD did not examine complication rates in detail by duration and region, nor did it conduct analyses to explain any variation according to the distribution of diabetes care practice.
The EURODIAB IDDM Complications Study, which was also initially a cross-sectional study of type 1 diabetes complications in 31 clinics in 16 European countries, showed less geographic variation in microvascular complications than either DiaComp or MSVDD. However, EURODIAB also showed that in eastern Europe (mean duration of diabetes 14.2 years), and in north-western Europe (mean duration of 15.4 years), the prevalence of retinopathy was high at 55.6% and 46.3%, respectively, as was the prevalence of neuropathy at 46.4% and 24.9%, respectively. 20 We found very similar patterns in DiaComp:central Europe stood out with the highest prevalence of retinopathy (30%), laser treatment (14%) and neuropathy (20%) for the short-duration group. This research has identified important differences in the geographic distribution of type 1 diabetes complications, in particular, high rates of retinopathy in central Europe, and the fundamental role of hypertension as a risk factor across all populations. Interestingly, these differences appear largely unexplained by our two measures of healthcare practice, IIT and SMBG. These findings, therefore, support appropriate screening in geographically 'high risk' areas, and the diligent monitoring (and treatment) of blood pressure among individuals with type 1 diabetes, even those with diabetes of relatively short duration.
